In this issue of Blood, Vrecenak et al report a significant improvement in the level of donor chimerism and immune tolerance in the dog model of major histocompatibility complex (MHC)-mismatched in utero hematopoietic cell transplantation (IUHCT). 1 
I
UHCT is a potentially curative treatment for many congenital hematologic disorders, but enthusiasm for its clinical use has waned because of the general lack of sustained donor cell engraftment. 2 There have been only a few successful cases of IUHCT with sustained donor T-cell chimerism in patients with X-linked severe combined immunodeficiency. 3, 4 To make progress in this field, it is essential to develop relevant large-animal models of IUHCT. However, for many years and in various animal models including the dog, donor cell engraftment after IUHCT has been either at very low levels or transient. 
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For personal use only. on April 5, 2017. by guest www.bloodjournal.org From to be in the early phase of the rapid expansion of double-positive cells in the thymus, prior to onset of the transition of hematopoiesis to the fetal bone marrow.
Among recipient dogs with greater than 10% donor chimerism, kidney grafts from the original bone marrow donor were accepted without histologic evidence of rejection. Using their optimized protocol, the authors achieved 88% frequency of engraftment in the absence of any form of conditioning or immunosuppression. The levels of donor chimerism achieved may actually be sufficient to treat many target disorders, including hemoglobinopathies and immunodeficiencies.
Although none of the recipients developed GVHD, concern persists about the potential for development of GVHD after IUHCT. In this study, the investigators partially T-cell-depleted the maternal bone marrow grafts, so that T cells contributed ;1% of the infused cell dose. The add-back of a portion of the CD34-depleted marrow cells to the CD34 1 selected cells from the maternal bone marrow appeared to increase the level of donor chimerism. Future studies will need to determine the optimal T-cell dose and the degree of MHC mismatch acceptable for tolerance and stable mixed hematopoietic chimerism. The significance of achieving high levels of donor chimerism and immune tolerance from an MHC-haploidentical graft is that a real barrier in IUHCT has finally been broken. For human patients, the authors are planning ultrasound-guided fetoscopic intravascular injection into the umbilical vein at the placental plate. They are initiating studies in nonhuman primates to technically mimic the clinical plan prior to beginning the studies in humans. If their approach is successful, it appears that in the not-too-distant future, IUHCT for hemoglobinopathies and immunodeficiencies that can be diagnosed by the end of the first in utero trimester may finally enter into the realm of clinical therapeutic reality.
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